About Singletto

Singletto develops novel antimicrobial solutions and singlet oxygen technology to protect against pathogens. Light-activated dyes are used in the company's solutions to generate singlet oxygen, which destroys pathogens of the common cold, seasonal flu, and COVID-19.

Company Highlights
Year Founded

2020

icon-altEmployees

11

Location (HQ)

USA

Since Last Funding

7 months

Monthly Website Visitors

538

icon-altTotal Investment Amt

$1.3M

Last Funding Round

Debt Financing

icon-altYoY Headcount Growth

-8.26%

Key Metrics

Senior Hires

NameLinkedin ProfilePositionDate Joined
John Doehttps://www.linkedin.com/in/johndoeCEOCEO
Jane Doehttps://www.linkedin.com/in/janedoeCTOCTO
John Smithhttps://www.linkedin.com/in/johnsmithCFOCFO
Jane Smithhttps://www.linkedin.com/in/janesmithCOOCOO
Get API access to complete private company database with growth metrics from 15 sources

Similar Companies

Health Care

Biotechnology

Biotechnology Research

Medical